HIV Envelope Protein gp120

Publication Title: 
Journal of Acquired Immune Deficiency Syndromes (1999)

We assessed willingness to participate in an HIV recombinant gp120 bivalent subtypes B/E candidate vaccine efficacy trial among 193 injection drug users (IDUs) attending drug treatment clinics in Bangkok, Thailand. IDUs previously enrolled in a prospective cohort study were invited to group sessions describing a potential trial, then completed questionnaires assessing comprehension and willingness to participate.

Author(s): 
MacQueen, K. M.
Vanichseni, S.
Kitayaporn, D.
Lin, L. S.
Buavirat, A.
Naiwatanakul, T.
Raktham, S.
Mock, P.
Heyward, W. L.
Des Jarlais, D. C.
Choopanya, K.
Mastro, T. D.
Publication Title: 
PloS One

BACKGROUND: We recently reported that palmitic acid (PA) is a novel and efficient CD4 fusion inhibitor to HIV-1 entry and infection. In the present report, based on in silico modeling of the novel CD4 pocket that binds PA, we describe discovery of highly potent PA analogs with increased CD4 receptor binding affinities (K(d)) and gp120-to-CD4 inhibition constants (K(i)). The PA analogs were selected to satisfy Lipinski's rule of drug-likeness, increased solubility, and to avoid potential cytotoxicity.

Author(s): 
Paskaleva, Elena E.
Xue, Jing
Lee, David Y.-W.
Shekhtman, Alexander
Canki, Mario
Publication Title: 
PloS One

BACKGROUND: Approximately 80% of all new HIV-1 infections are acquired through sexual contact. Currently, there is no clinically approved microbicide, indicating a clear and urgent therapeutic need. We recently reported that palmitic acid (PA) is a novel and specific inhibitor of HIV-1 fusion and entry. Mechanistically, PA inhibits HIV-1 infection by binding to a novel pocket on the CD4 receptor and blocks efficient gp120-to-CD4 attachment.

Author(s): 
Lin, Xudong
Paskaleva, Elena E.
Chang, William
Shekhtman, Alexander
Canki, Mario
Subscribe to RSS - HIV Envelope Protein gp120